NCT04050462 2025-10-16
Nivolumab Combined With BMS-986253 in HCC Patients
NYU Langone Health
Phase 2 Terminated
Clinical Trials
3 trialsNCT03697564 2025-08-06
Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer
University of California, San Diego
Phase 2 Completed
NCT03927105 2024-03-18
Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
University of Michigan Rogel Cancer Center
Phase 2 Completed